(NASDAQ: AGIO) Agios Pharmaceuticals's forecast annual revenue growth rate of 97.7% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Agios Pharmaceuticals's revenue in 2025 is $36,498,000.On average, 4 Wall Street analysts forecast AGIO's revenue for 2025 to be $2,872,829,813, with the lowest AGIO revenue forecast at $2,585,203,055, and the highest AGIO revenue forecast at $3,231,503,819. On average, 4 Wall Street analysts forecast AGIO's revenue for 2026 to be $7,834,677,876, with the lowest AGIO revenue forecast at $6,864,080,807, and the highest AGIO revenue forecast at $9,080,296,546.
In 2027, AGIO is forecast to generate $16,830,863,649 in revenue, with the lowest revenue forecast at $13,374,071,301 and the highest revenue forecast at $21,978,809,661.